Cary, N.C.-based NephroGenex, a biotech developing personalized therapies for kidney disease, raised $3.3 million of an expected $26.8 million first funding round, VentureWire reports (subscription required), citing an SEC filing (no link available). There’s another report that cites PE Wire here.

Care Capital, BioStratum and Vanderbilt University are all 10 percent investors in the company, according to VentureWire.

NephroGenex’s aim is to tease apart a variety of different diseases that are generally lumped together as “kidney disease” by closely examining the activity of genes in the kidney’s filtration unit, the glomerulus. In so doing, the company hopes to figure out which of these conditions might be most responsive to drug treatment. In May, the company licensed commercial rights to BioStratum’s drug Pyridorin, and hopes to accelerate clinical trials of the drug by identifying patients whose kidney disease is progressing rapidly.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.

Author
Topics